- Home
- SGA vs IMA Comparison
SGA vs IMA Comparison
Compare SGA & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGA | IMA |
|---|---|---|
| Founded | 1986 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.6M | 66.3M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SGA | IMA |
|---|---|---|
| Price | $8.97 | $5.13 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 17.6K | 10.0K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | ★ 9.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $124,829,000.00 | $800,000.00 |
| Revenue This Year | $6.74 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.65 | N/A |
| 52 Week Low | $8.24 | $3.94 |
| 52 Week High | $13.05 | $9.20 |
Technical Indicators
Market Signals| Indicator | SGA | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 38.71 |
| Support Level | $8.36 | $3.94 |
| Resistance Level | $9.42 | $6.13 |
| Average True Range (ATR) | 0.30 | 0.28 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 25.24 | 21.02 |
Price Performance
Historical ComparisonAbout SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.